암 지지요법 약물 시장 : 세계 예측(2026-2032년)

The Cancer Supportive Care Drugs Market is projected to grow by USD 246.97 million at a CAGR of 7.00% by 2032.

Cancer supportive care drugs are essential therapies used to prevent, reduce, or manage the adverse effects of cancer and its treatment, including chemotherapy, immunotherapy, radiation therapy, targeted therapy, and stem cell transplantation. These drugs address high-burden clinical needs such as chemotherapy-induced nausea and vomiting, cancer pain, neutropenia, anemia, infection risk, bone metastasis complications, mucositis, cachexia, thrombocytopenia, and treatment-related gastrointestinal or dermatologic toxicities. As oncology treatment becomes more personalized and increasingly intensive, supportive oncology has moved from an adjunct service to a core component of multidisciplinary cancer care. The clinical objective is no longer limited to symptom relief; it includes preserving dose intensity, reducing avoidable hospitalizations, improving adherence to anticancer regimens, enhancing patient-reported outcomes, and supporting quality of life across the cancer journey. Rising cancer incidence, aging populations, longer cancer survivorship, expanded access to systemic therapies, and broader adoption of immuno-oncology have increased the need for evidence-based supportive care pathways. Regulatory agencies, oncology societies, and health systems increasingly emphasize guideline-concordant symptom management, antimicrobial stewardship, opioid risk mitigation, biosimilar adoption, and real-world safety monitoring. These shifts are shaping demand for antiemetics, hematopoietic growth factors, analgesics, bone-modifying agents, iron therapies, corticosteroids, antibiotics, antifungals, antidiarrheals, appetite stimulants, and other supportive oncology medications. The competitive and clinical landscape is also being influenced by biosimilars, oral formulations, long-acting injectables, digital adherence tools, pharmacogenomics, and integrated palliative care models. For stakeholders across pharmaceutical development, oncology services, payers, and distribution networks, cancer supportive care drugs represent a strategically important category tied directly to cancer treatment continuity, patient safety, and health system efficiency.

Transformative Shifts in the Cancer Supportive Care Landscape

The cancer supportive care drugs landscape is undergoing structural change as oncology care shifts toward longer treatment durations, combination regimens, outpatient administration, and survivorship-focused management. Modern cancer therapies have altered toxicity profiles, creating new supportive care demands beyond traditional chemotherapy-associated complications. Immune checkpoint inhibitors can trigger immune-related adverse events requiring corticosteroids and immunosuppressive management, while targeted therapies and antibody-drug conjugates are associated with dermatologic, gastrointestinal, hematologic, ocular, and pulmonary toxicities that require proactive intervention. At the same time, conventional needs such as antiemetic protection, neutropenia prevention, cancer pain control, and bone health remain central to clinical practice. A major transformation is the increasing reliance on evidence-based clinical pathways aligned with recognized oncology supportive care guidelines. These pathways are standardizing the use of 5-HT3 receptor antagonists, NK1 receptor antagonists, colony-stimulating factors, erythropoiesis-stimulating agents where appropriate, bisphosphonates, RANK ligand inhibitors, and antimicrobial prophylaxis in defined risk settings. Another important shift is the expansion of biosimilars in supportive oncology, particularly for hematopoietic growth factors, which has improved formulary flexibility and intensified focus on cost-effective prescribing without compromising regulatory standards for safety, purity, and potency. Care delivery is also moving closer to the patient through ambulatory infusion centers, home-based oncology support, specialty pharmacy coordination, tele-oncology symptom triage, and oral oncology adherence programs. Payers and providers are increasingly measuring avoidable emergency visits, febrile neutropenia admissions, uncontrolled nausea, opioid-related safety events, and treatment discontinuation as indicators of supportive care performance. These transformations are encouraging drug developers to prioritize differentiated safety profiles, convenient dosing, compatibility with complex oncology regimens, and evidence that demonstrates measurable impact on treatment persistence and patient-centered outcomes.

Cumulative Impact of Artificial Intelligence on Supportive Oncology

Artificial intelligence is beginning to influence cancer supportive care drugs by improving risk prediction, toxicity surveillance, treatment personalization, and operational efficiency across oncology settings. AI-enabled models can analyze electronic health records, laboratory trends, treatment regimens, comorbidities, prior toxicities, genomics, and patient-reported outcomes to identify individuals at increased risk of febrile neutropenia, chemotherapy-induced nausea and vomiting, opioid complications, immune-related adverse events, malnutrition, dehydration, infection, or unplanned hospitalization. When validated and integrated responsibly, these tools can support earlier intervention with antiemetics, growth factors, analgesic optimization, antimicrobial prophylaxis, hydration support, or specialist referral. AI is also strengthening pharmacovigilance by detecting safety signals from real-world data, spontaneous adverse event reports, claims datasets, and clinical documentation. Natural language processing can capture symptoms that are often under-coded, such as fatigue, mucositis severity, appetite loss, neuropathic pain, and functional decline. In drug development, AI can assist with trial design, eligibility screening, toxicity clustering, biomarker exploration, and comparative effectiveness research for supportive oncology interventions. In clinical operations, predictive analytics can help infusion centers anticipate supportive medication needs, reduce treatment delays, optimize inventory, and coordinate specialty pharmacy dispensing. However, the cumulative impact of artificial intelligence depends on data quality, model transparency, equitable representation, clinician oversight, privacy protection, and alignment with regulatory expectations for software used in healthcare decision support. AI should not replace clinical judgment; rather, it can enhance precision supportive care by helping oncology teams identify risk earlier, standardize guideline-based interventions, and monitor outcomes continuously. As healthcare systems increasingly link reimbursement and quality measurement to symptom control and avoidable acute care utilization, AI-supported supportive oncology workflows are becoming a practical differentiator for high-performing cancer programs.

Key Regional Insights Across Cancer Supportive Care Drugs

Asia-Pacific is experiencing growing emphasis on cancer supportive care drugs as expanding oncology infrastructure, higher cancer detection, aging demographics, and wider access to systemic cancer therapies increase the need for antiemetics, hematopoietic growth factors, analgesics, bone-targeted therapies, antimicrobials, and nutritional support. The region is highly diverse: advanced health systems are accelerating protocol-driven supportive oncology and digital symptom monitoring, while emerging markets are focused on access, affordability, and essential medicine availability. North America has mature oncology treatment networks, extensive guideline adoption, strong specialty pharmacy capabilities, and established reimbursement mechanisms that support broad use of supportive care medicines, particularly in outpatient and community oncology settings. Clinical priorities include reducing chemotherapy-related hospitalizations, managing cancer pain safely, integrating palliative care earlier, and optimizing biosimilar use. Latin America is strengthening supportive cancer care through public oncology programs, private-sector treatment access, and regional cancer control initiatives, but variations in reimbursement, medicine availability, and diagnostic capacity continue to influence adoption patterns. In Europe, strong clinical guideline frameworks, pharmacovigilance systems, health technology assessment processes, and biosimilar policies shape supportive care prescribing, with increasing focus on value-based oncology, survivorship, and equitable access across countries. The Middle East is investing in oncology centers, national cancer strategies, and advanced treatment capabilities, increasing the importance of standardized supportive care protocols, pain management, infection prevention, and treatment adherence support. Across Africa, supportive oncology needs are significant due to rising cancer burden, late-stage diagnosis in many settings, constrained oncology workforce capacity, and gaps in access to essential medicines; priorities include strengthening palliative care, improving supply chains for pain relief and antiemetics, expanding infection management, and integrating supportive care into national cancer control plans. Across all regions, durable opportunities are tied to affordability, regulatory harmonization, clinician education, real-world evidence generation, and patient-centered delivery models.

Key Group Insights Across Global Healthcare Alliances

ASEAN countries are advancing cancer supportive care through expanding oncology services, public health insurance reforms, and regional efforts to improve access to essential cancer medicines, although disparities remain between urban cancer centers and underserved areas. Demand is closely linked to chemotherapy availability, supportive antiemetic protocols, infection prevention, pain relief, and affordability of biologic and biosimilar options. The GCC is characterized by substantial investment in specialist oncology infrastructure, health system modernization, and national cancer strategies, creating favorable conditions for protocol-based supportive care, advanced infusion services, and digital patient monitoring. The European Union places strong emphasis on medicine safety, pharmacovigilance, biosimilar confidence, health technology assessment, and cross-border policy coordination, making it a key environment for evidence-based supportive oncology adoption and access initiatives. BRICS countries combine large patient populations, expanding cancer treatment capacity, domestic pharmaceutical manufacturing capabilities, and significant access challenges, resulting in strong policy attention to affordability, local production, generic and biosimilar use, and essential medicine distribution. G7 countries generally have advanced oncology ecosystems, high adoption of clinical guidelines, robust regulatory oversight, and strong real-world evidence capabilities, supporting sophisticated use of supportive care drugs across chemotherapy, immunotherapy, radiation therapy, and survivorship settings. NATO member countries overlap substantially with high-income oncology systems in North America and Europe but also include varied reimbursement and procurement environments, making supply resilience, antimicrobial stewardship, and standardized emergency preparedness relevant to supportive oncology medicines. Across these groups, policy priorities increasingly converge around quality-of-life improvement, continuity of anticancer treatment, reduction of unplanned acute care, safe opioid and antimicrobial use, and cost-effective access to high-quality supportive care drugs.

Key Country Insights for Cancer Supportive Care Drugs

The United States has a highly developed supportive oncology environment shaped by clinical pathways, specialty pharmacy networks, payer utilization management, outpatient cancer care, biosimilar adoption, and strong emphasis on reducing avoidable emergency department use and hospital admissions. Canada prioritizes equitable access through provincial cancer systems, evidence-based formularies, palliative care integration, and supportive medication coverage decisions. Mexico is expanding oncology access while managing variability in public and private coverage, making affordability and reliable supply of antiemetics, analgesics, antibiotics, and growth factors central considerations. Brazil has significant oncology demand across public and private systems, with supportive care needs tied to chemotherapy access, pain management, infection control, and regional care disparities. The United Kingdom emphasizes guideline-led supportive oncology, early palliative care, medicine optimization, and systematic evaluation of clinical value within a publicly funded health system. Germany combines advanced oncology infrastructure, strong hospital and ambulatory care networks, and broad use of evidence-based supportive therapies, supported by rigorous regulatory and reimbursement standards. France places substantial focus on cancer care quality, pharmacovigilance, supportive care integration, and patient-centered oncology pathways. Russia faces supportive care requirements across a large geography, with policy attention on domestic production, oncology modernization, and access to essential cancer medicines. Italy and Spain maintain well-established oncology systems where supportive care is increasingly linked to survivorship, symptom control, biosimilar utilization, and regional reimbursement frameworks. China is rapidly expanding oncology capacity, improving drug access through regulatory reforms and reimbursement updates, and increasing the use of supportive care drugs alongside broader uptake of systemic cancer treatments. India has a large and diverse cancer care environment where affordability, generic availability, palliative care access, and urban-rural disparities strongly shape supportive oncology practice. Japan has advanced cancer treatment infrastructure, an aging population, and strong focus on antiemetic control, neutropenia prevention, pain management, and safety monitoring. Australia supports evidence-based supportive care through national cancer policies, reimbursement mechanisms, and integrated oncology services. South Korea combines advanced cancer screening, modern treatment centers, digital health capabilities, and strong clinical adoption of supportive therapies to improve treatment continuity and patient outcomes.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that demonstrates how cancer supportive care drugs improve clinically meaningful outcomes, including reduced febrile neutropenia, lower rates of uncontrolled nausea and vomiting, fewer treatment delays, improved pain control, reduced skeletal-related complications, better adherence, and fewer unplanned acute care visits. Product strategies should emphasize differentiated tolerability, simplified dosing, compatibility with combination oncology regimens, and usability in outpatient, home-based, and specialty pharmacy models. Stakeholders should strengthen alignment with oncology clinical guidelines and invest in real-world evidence programs that capture patient-reported outcomes, medication persistence, hospitalization patterns, and safety signals across diverse populations. Access strategies should reflect regional differences in reimbursement, procurement, and essential medicine availability, with particular attention to affordable formulations, biosimilars, generics, and resilient supply chains. Partnerships with oncology providers should focus on protocol implementation, clinician education, nurse-led symptom management, pharmacist-supported medication review, and digital adherence tools. Companies and healthcare organizations should also prepare for artificial intelligence-enabled supportive care by ensuring data interoperability, ethical model validation, privacy compliance, and transparent clinical governance. For high-growth and access-constrained settings, the most impactful actions include improving availability of essential supportive medicines, supporting palliative care training, expanding cold-chain and distribution capabilities where needed, and generating local evidence that reflects real-world oncology practice. Across all markets, leaders should treat supportive care not as a secondary category but as a strategic pillar of cancer treatment quality, patient experience, and healthcare system efficiency.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, data-backed sources and cross-validation across authoritative healthcare references. The methodology emphasizes analysis of oncology clinical guidelines, regulatory agency publications, public health cancer control resources, peer-reviewed medical literature, pharmacovigilance frameworks, health technology assessment documentation, and recognized global health datasets related to cancer burden, treatment toxicity, access to medicines, and supportive oncology practices. The research process includes thematic mapping of major drug classes used in cancer supportive care, assessment of clinical use cases across chemotherapy, immunotherapy, radiation therapy, targeted therapy, and palliative care, and evaluation of regional policy and healthcare delivery dynamics. Insights are synthesized without relying on market sizing, market share, or forecasting. The analysis considers qualitative indicators such as guideline adoption, reimbursement structures, access barriers, biosimilar policy, clinical workflow integration, safety monitoring, and patient-centered outcome priorities. Regional, group, and country insights are interpreted through the lens of healthcare infrastructure, cancer treatment availability, regulatory maturity, medicine access, and evolving standards of care. To maintain reliability, claims are framed around established clinical and policy trends rather than speculative commercial projections. This approach supports an optimized but evidence-grounded view of cancer supportive care drugs for stakeholders seeking strategic clarity in a complex and rapidly evolving oncology ecosystem.

Conclusion

Cancer supportive care drugs are becoming increasingly central to oncology as health systems work to improve treatment tolerability, maintain anticancer therapy continuity, reduce preventable complications, and enhance quality of life for people living with cancer. The category spans a broad range of medicines that address nausea and vomiting, neutropenia, anemia, pain, infection, bone complications, nutritional decline, gastrointestinal toxicity, and immune-mediated adverse events. Transformative trends include guideline-based care pathways, biosimilar adoption, outpatient and home-based oncology support, real-world evidence generation, and the emerging use of artificial intelligence for predictive risk management and pharmacovigilance. Regional and country dynamics show that advanced oncology systems are refining supportive care through quality metrics and digital integration, while emerging and resource-constrained settings continue to prioritize access to essential supportive medicines, affordability, workforce training, and palliative care capacity. For industry leaders, success will depend on combining clinical credibility with practical access strategies, patient-centered evidence, resilient supply chains, and technology-enabled care coordination. As cancer treatment continues to evolve, supportive care drugs will remain indispensable to safer, more effective, and more humane oncology practice.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Supportive Care Drugs Market, by Drug Class

• 7.1. Introduction
• 7.2. Antiemetics
  • 7.2.1. 5-HT3 Antagonists
  • 7.2.2. NK1 Antagonists
  • 7.2.3. Olanzapine
• 7.3. Bone-Modifying Agents
  • 7.3.1. Bisphosphonates
  • 7.3.2. RANKL Inhibitors
• 7.4. Hematopoietic Agents
  • 7.4.1. Erythropoiesis Stimulating Agents
    • 7.4.1.1. Darbepoetin
    • 7.4.1.2. Epoetin
  • 7.4.2. Myeloprotection Agents
  • 7.4.3. Thrombopoietin Receptor Agonists
• 7.5. Pain Management Agents
  • 7.5.1. Non-Opioids
    • 7.5.1.1. Acetaminophen
    • 7.5.1.2. Adjuvant Analgesics
    • 7.5.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 7.5.2. Opioids

8. Cancer Supportive Care Drugs Market, by Cancer Type

• 8.1. Introduction
• 8.2. Hematologic Malignancies
  • 8.2.1. Leukemias
  • 8.2.2. Lymphomas
  • 8.2.3. Multiple Myeloma
  • 8.2.4. Myelodysplastic Syndromes
• 8.3. Solid Tumors
  • 8.3.1. Breast Cancer
  • 8.3.2. Colorectal Cancer
  • 8.3.3. Gastrointestinal Cancers
  • 8.3.4. Head And Neck Cancer
  • 8.3.5. Lung Cancer
  • 8.3.6. Ovarian Cancer
  • 8.3.7. Prostate Cancer

9. Cancer Supportive Care Drugs Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Intravenous
• 9.3. Oral
• 9.4. Rectal
• 9.5. Subcutaneous
• 9.6. Topical
• 9.7. Transdermal

10. Cancer Supportive Care Drugs Market, by Originator Type

• 10.1. Introduction
• 10.2. Biosimilar
• 10.3. Branded
• 10.4. Generic

11. Cancer Supportive Care Drugs Market, by Age Group

• 11.1. Introduction
• 11.2. Adult
• 11.3. Geriatric
• 11.4. Pediatric

12. Cancer Supportive Care Drugs Market, by Indication

• 12.1. Introduction
• 12.2. Bone Metastases Related Events
• 12.3. Cachexia & Anorexia
• 12.4. Cancer Pain
• 12.5. Chemotherapy-Induced Nausea & Vomiting
  • 12.5.1. Acute CINV
  • 12.5.2. Breakthrough/Refractory CINV
  • 12.5.3. Delayed CINV
• 12.6. Diarrhea
• 12.7. Mucositis And Stomatitis
• 12.8. Myelosuppression
  • 12.8.1. Chemotherapy-Induced Anemia
  • 12.8.2. Chemotherapy-Induced Neutropenia

13. Cancer Supportive Care Drugs Market, by Care Setting

• 13.1. Introduction
• 13.2. Inpatient
• 13.3. Outpatient

14. Cancer Supportive Care Drugs Market, by Distribution Channel

• 14.1. Introduction
• 14.2. Hospital Pharmacies
• 14.3. Mail-Order And Online Pharmacies
• 14.4. Retail Pharmacies
• 14.5. Specialty Pharmacies

15. Cancer Supportive Care Drugs Market, by End User

• 15.1. Introduction
• 15.2. Ambulatory Surgery Centers
• 15.3. Homecare Settings
• 15.4. Hospitals
• 15.5. Oncology Clinics And Infusion Centers

16. Cancer Supportive Care Drugs Market, by Region

• 16.1. Asia-Pacific
• 16.2. North America
• 16.3. Latin America
• 16.4. Europe
• 16.5. Middle East
• 16.6. Africa

17. Cancer Supportive Care Drugs Market, by Group

• 17.1. ASEAN
• 17.2. GCC
• 17.3. European Union
• 17.4. BRICS
• 17.5. G7
• 17.6. NATO

18. Cancer Supportive Care Drugs Market, by Country

• 18.1. United States
• 18.2. Germany
• 18.3. China
• 18.4. Japan
• 18.5. India
• 18.6. United Kingdom
• 18.7. Canada
• 18.8. Russia
• 18.9. Brazil
• 18.10. Italy
• 18.11. Mexico
• 18.12. France
• 18.13. Spain
• 18.14. Australia
• 18.15. South Korea

19. Competitive Landscape

• 19.1. Market Share Analysis, 2025
• 19.2. FPNV Positioning Matrix, 2025
• 19.3. Market Concentration Analysis, 2025
  • 19.3.1. Concentration Ratio (CR)
  • 19.3.2. Herfindahl Hirschman Index (HHI)
• 19.4. Recent Developments & Impact Analysis, 2025
• 19.5. Product Portfolio Analysis, 2025
• 19.6. Benchmarking Analysis, 2025

20. Company Profiles

• 20.1. Abbott Laboratories
• 20.2. Acacia Pharma Group Plc
• 20.3. Accord Healthcare Limited
• 20.4. Amgen Inc.
• 20.5. APR Applied Pharma Research S.A. by Relief Therapeutics Holding AG
• 20.6. AstraZeneca plc
• 20.7. Coherus BioSciences, Inc.
• 20.8. Daiichi Sankyo Company, Limited
• 20.9. Dr. Reddy's Laboratories Ltd.
• 20.10. F. Hoffmann-La Roche Ltd.
• 20.11. Fresenius Kabi AG
• 20.12. Fresenius SE & Co. KGaA
• 20.13. GlaxoSmithKline plc
• 20.14. Helsinn Healthcare SA
• 20.15. Heron Therapeutics, Inc.
• 20.16. Ipsen S.A.
• 20.17. Johnson & Johnson Services, Inc.
• 20.18. Lupin Limited
• 20.19. Novartis AG
• 20.20. Pfizer Inc.
• 20.21. Sanofi S.A.
• 20.22. Teva Pharmaceutical Industries Ltd.
• 20.23. Viatris Inc.